TrialBlood advances2026

WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study.

Yoshiko Hashii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.